Skip to main content

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Access & Citations

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

Online attention

Altmetric score 12
  • 20 tweeters
  • 79 Mendeley

This article is in the 84th percentile (ranked 36,561st) of the 240,778 tracked articles of a similar age in all journals and the 70th percentile (ranked 23rd) of the 78 tracked articles of a similar age in Journal for ImmunoTherapy of Cancer

View more on Altmetric

Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.